Country: Canada
Language: English
Source: Health Canada
ROSIGLITAZONE (ROSIGLITAZONE MALEATE); METFORMIN HYDROCHLORIDE
PHARMASCIENCE INC
A10BD03
METFORMIN AND ROSIGLITAZONE
2MG; 1000MG
TABLET
ROSIGLITAZONE (ROSIGLITAZONE MALEATE) 2MG; METFORMIN HYDROCHLORIDE 1000MG
ORAL
100
Prescription
BIGUANIDES
Active ingredient group (AIG) number: 0248901004; AHFS:
CANCELLED PRE MARKET
2017-08-03
PRODUCT MONOGRAPH PR PMS-ROSIGLITAZONE-METFORMIN rosiglitazone maleate/metformin hydrochloride 1 mg/500 mg Tablets 1 mg rosiglitazone (as rosiglitazone maleate) and 500 mg metformin hydrochloride 2 mg/500 mg Tablets 2 mg rosiglitazone (as rosiglitazone maleate) and 500 mg metformin hydrochloride 4 mg/500 mg Tablets 4 mg rosiglitazone (as rosiglitazone maleate) and 500 mg metformin hydrochloride 2 mg/1000 mg Tablets 2 mg rosiglitazone (as rosiglitazone maleate) and 1000 mg metformin hydrochloride 4 mg/1000 mg Tablets 4 mg rosiglitazone (as rosiglitazone maleate) and 1000 mg metformin hydrochloride Antidiabetic Agent PHARMASCIENCE INC. DATE OF REVISION: 6111 Royalmount Ave. suite 100 July 12, 2013 Montreal, Canada H4P 2T4 Submission Control No. 166029 _ _ _pms-ROSIGLITAZONE-METFORMIN Product Monograph _ _Page 2 of 56_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................ 4 WARNINGS AND PRECAUTIONS ................................................................................. 5 ADVERSE REACTIONS ................................................................................................. 14 DRUG INTERACTIONS ................................................................................................. 19 DOSAGE AND ADMINISTRATION ............................................................................. 22 OVERDOSAGE ................................................................................................................ 23 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 24 STORAGE AND STABILITY .......................................................................... Read the complete document